Between the dupilumab group and the placebo group, significantly more patients receiving dupilumab had a FeNO less than 25 ppb at week 24 (56.9% vs. 10.8%), signaling lower type 2 airway inflammation.

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Castro M, Papi A, Porsbjerg C, et al. Evaluating the effect of dupilumab on type 2 airway inflammation and mucus plugging in patients with uncontrolled moderate-to-severe asthma: the VESTIGE trial.

Dual-action approach targeting inflammation shows potential as Type 1 diabetes treatment. ScienceDaily . Retrieved July 23, 2025 from www.sciencedaily.com / releases / 2025 / 05 / 250507141132.htm ...

Inflammation in human airways is associated with such conditions as asthma, allergic rhinitis and chronic cough. Skip to main content. Your source for the latest research news.